- Home
- BAM vs REGN Comparison
BAM vs REGN Comparison
Compare BAM & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BAM | REGN |
|---|---|---|
| Founded | 2022 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.2B | 73.9B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | BAM | REGN |
|---|---|---|
| Price | $53.54 | $754.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 23 |
| Target Price | $63.38 | ★ $795.74 |
| AVG Volume (30 Days) | ★ 2.9M | 1.1M |
| Earning Date | 11-07-2025 | 02-03-2026 |
| Dividend Yield | ★ 3.25% | 0.47% |
| EPS Growth | ★ 42.52 | 2.88 |
| EPS | 1.62 | ★ 41.59 |
| Revenue | $4,486,000,000.00 | ★ $14,247,800,000.00 |
| Revenue This Year | $34.55 | $1.95 |
| Revenue Next Year | $14.64 | $5.47 |
| P/E Ratio | $33.19 | ★ $17.82 |
| Revenue Growth | ★ 10.85 | 2.89 |
| 52 Week Low | $41.78 | $476.49 |
| 52 Week High | $64.10 | $790.98 |
Technical Indicators
Market Signals| Indicator | BAM | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 61.90 |
| Support Level | $52.79 | $689.88 |
| Resistance Level | $55.93 | $753.61 |
| Average True Range (ATR) | 1.24 | 20.54 |
| MACD | 0.34 | -4.06 |
| Stochastic Oscillator | 56.58 | 65.55 |
Price Performance
Historical ComparisonAbout BAM Brookfield Asset Management Inc Limited Voting Shares
Brookfield Asset Management Ltd engages in providing alternative asset management services through an ownership interest in a alternative asset management business. It offers a range of alternative investment products to investors around the world including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies, and private wealth investors.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).